Search

Your search keyword '"Lalani, A. S."' showing total 373 results
Start Over Author "Lalani, A. S."
373 results on '"Lalani, A. S."'

3. Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast CancerBiomarker Analysis of the Phase III NALA Study in HER2+ MBC

Author

Saura, Cristina, Matito, Judit, Oliveira, Mafalda, Wildiers, Hans, Brufksy, Adam M, Waters, Simon H, Hurvitz, Sara A, Moy, Beverly, Kim, Sung-Bae, Gradishar, William J, Queiroz, Geraldo Silva, Cronemberger, Eduardo, Wallweber, Gerald J, Bebchuk, Judith, Keyvanjah, Kiana, Lalani, Alshad S, Bryce, Richard, Vivancos, Ana, Eli, Lisa D, and Delaloge, Suzette

Subjects
Breast Cancer, Cancer, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Breast Neoplasms, Capecitabine, Correlation of Data, Female, Humans, Lapatinib, Neoplasm Metastasis, Quinolines, Retreatment, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeNeratinib plus capecitabine (N+C) demonstrated significant progression-free survival (PFS) benefit in NALA (NCT01808573), a randomized phase III trial comparing N+C with lapatinib + capecitabine (L+C) in 621 patients with HER2-positive (HER2+) metastatic breast cancer (MBC) who had received ≥2 prior HER2-directed regimens in the metastatic setting. We evaluated correlations between exploratory biomarkers and PFS.Patients and methodsSomatic mutations were evaluated by next-generation sequencing on primary or metastatic samples. HER2 protein expression was evaluated by central IHC, H-score, and VeraTag/HERmark. p95 expression (truncated HER2) was measured by VeraTag. HRs were estimated using unstratified Cox proportional hazards models.ResultsFour hundred and twenty samples had successful sequencing: 34.0% had PIK3CA mutations and 5.5% had HER2 (ERBB2) mutations. In the combined patient populations, PIK3CA mutations trended toward shorter PFS [wild-type vs. mutant, HR = 0.81; 95% confidence interval (CI), 0.64-1.03], whereas HER2 mutations trended toward longer PFS [HR = 1.69 (95% CI, 0.97-3.29)]. Higher HER2 protein expression was associated with longer PFS [IHC 3+ vs. 2+, HR = 0.67 (0.54-0.82); H-score ≥240 versus

Published
2021

4. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

Author

Oaknin, Ana, Friedman, Claire F, Roman, Lynda D, D’Souza, Anishka, Brana, Irene, Bidard, François-Clement, Goldman, Jonathan, Alvarez, Edwin A, Boni, Valentina, ElNaggar, Adam C, Passalacqua, Rodolfo, T.M., Khanh, Santin, Alessandro D, Keyvanjah, Kiana, Xu, Feng, Eli, Lisa D, Lalani, Alshad S, Bryce, Richard P, Hyman, David M, Meric-Bernstam, Funda, Solit, David B, and Monk, Bradley J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Administration, Oral, Adult, Diarrhea, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Mutation, Nausea, Neoplasm Recurrence, Local, Progression-Free Survival, Protein Kinase Inhibitors, Quinolines, Receptor, ErbB-2, Response Evaluation Criteria in Solid Tumors, Severity of Illness Index, Uterine Cervical Neoplasms, Cervical cancer, HER2 mutant, Neratinib, Clinical trial, Tyrosine kinase inhibitor, Receptor, erbB-2, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

ObjectiveSomatic HER2 mutations occur in ~5% of cervical cancers and are considered oncogenic and associated with poor prognosis. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is active in multiple HER2-mutant cancers. SUMMIT is a phase II basket trial investigating the efficacy and safety of neratinib in solid tumors.MethodsPatients with HER2-mutant, persistent, metastatic/recurrent cervical cancer with disease progression after platinum-based treatment for advanced/recurrent disease received oral neratinib 240 mg/day with mandatory loperamide prophylaxis during cycle 1. The primary endpoint was confirmed objective response rate (ORR). Secondary endpoints included: response duration (DOR); clinical benefit rate (CBR); progression-free survival (PFS); overall survival (OS); safety.ResultsSixteen eligible patients were enrolled; 10 (62.5%) had endocervical adenocarcinoma. The most common HER2 mutation was S310F (63% of patients). Three of 12 RECIST-measurable patients had confirmed partial responses (ORR 25%; 95%CI 5.5-57.2%); 3 had stable disease ≥16 weeks (CBR 50%; 95%CI 21.1-78.9%). DOR for responders were 5.6, 5.9, and 12.3 months. Median PFS was 7.0 months (95%CI 0.7-18.3 months); median OS was 16.8 months (95%CI 4.1-NE months). Diarrhea (75%), nausea (44%), and decreased appetite (38%) were the most common adverse events. One patient (6%) reported grade 3 diarrhea. There were no grade 4 events, and no diarrhea-related treatment discontinuations.ConclusionsNeratinib monotherapy showed evidence of activity in heavily pretreated patients with HER2-mutant cervical cancer, with no new safety signals. Given the few effective options for cervical cancer after platinum-based therapy failure, neratinib warrants further investigation in this molecularly defined patient population.Trial registration numberNCT01953926 (ClinicalTrials.gov), 2013-002872-42 (EudraCT).

Published
2020

5. Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention.

Author

Chaitoff, Alexander, Bendicksen, Liam, Feldman, William B., Zheutlin, Alexander R., and Lalani, Hussain S.

Subjects
MEDICARE Part D, ANTIOBESITY agents, GLUCAGON-like peptide-1 receptor, INFLATION Reduction Act of 2022, HEALTH & Nutrition Examination Survey, CARDIOVASCULAR diseases, MYOCARDIAL infarction
Abstract

This document discusses the potential implications of expanding access to the medication semaglutide for Medicare beneficiaries with elevated body mass index (BMI). The study found that approximately 1 in 7 beneficiaries with elevated BMI would be newly eligible for semaglutide, but the majority would remain ineligible if a narrow definition of established cardiovascular disease (CVD) is used. The document highlights the importance of weight control for patients with elevated BMI and suggests that the definition of established CVD used by Part D plans for coverage of semaglutide could have significant public health implications. However, the document also acknowledges that access to semaglutide may be impacted by factors such as out-of-pocket costs, formulary placement, drug shortages, and utilization management strategies. The potential budgetary impacts of expanding access to semaglutide are also discussed, with estimates suggesting that it could generate over $10 billion in new annual federal spending. The document concludes by emphasizing the need for near-term policy solutions to control these budgetary impacts. [Extracted from the article]

Published
2024
Full Text
View/download PDF

11. Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

Author

Veeraraghavan, Jamunarani, Gutierrez, Carolina, Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Giuliano, Mario, Shea, Martin J., Mitchell, Tamika, Wang, Tao, Nanda, Sarmistha, Pereira, Resel, Davis, Robert, Goutsouliak, Kristina, Qin, Lanfang, De Angelis, Carmine, Diala, Irmina, Lalani, Alshad S., Nagi, Chandandeep, Hilsenbeck, Susan G., Rimawi, Mothaffar F., Osborne, C. Kent, and Schiff, Rachel

Published
2021
Full Text
View/download PDF

17. Use of Chemokine Receptors by Poxviruses

Author

Lalani, Alshad S., Masters, Jennefer, Zeng, Wei, Barrett, John, Pannu, Rajeet, Everett, Helen, Arendt, Christopher W., and McFadden, Grant

Published
1999

19. Supplementary Figure S2 from Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Piha-Paul, Sarina A., primary, Won, Helen H., primary, Schram, Alison M., primary, Saura, Cristina, primary, Loi, Sherene, primary, Lu, Janice, primary, Shapiro, Geoffrey I., primary, Juric, Dejan, primary, Mayer, Ingrid A., primary, Arteaga, Carlos L., primary, de la Fuente, Macarena I., primary, Brufksy, Adam M., primary, Spanggaard, Iben, primary, Mau-Sørensen, Morten, primary, Arnedos, Monica, primary, Moreno, Victor, primary, Boni, Valentina, primary, Sohn, Joohyuk, primary, Schwartzberg, Lee S., primary, Gonzàlez-Farré, Xavier, primary, Cervantes, Andrés, primary, Bidard, François-Clement, primary, Gorelick, Alexander N., primary, Lanman, Richard B., primary, Nagy, Rebecca J., primary, Ulaner, Gary A., primary, Chandarlapaty, Sarat, primary, Jhaveri, Komal, primary, Gavrila, Elena I., primary, Zimel, Catherine, primary, Selcuklu, S. Duygu, primary, Melcer, Myra, primary, Samoila, Aliaksandra, primary, Cai, Yanyan, primary, Scaltriti, Maurizio, primary, Mann, Grace, primary, Xu, Feng, primary, Eli, Lisa D., primary, Dujka, Melanie, primary, Lalani, Alshad S., primary, Bryce, Richard, primary, Baselga, José, primary, Taylor, Barry S., primary, Solit, David B., primary, Meric-Bernstam, Funda, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

20. Data from Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Piha-Paul, Sarina A., primary, Won, Helen H., primary, Schram, Alison M., primary, Saura, Cristina, primary, Loi, Sherene, primary, Lu, Janice, primary, Shapiro, Geoffrey I., primary, Juric, Dejan, primary, Mayer, Ingrid A., primary, Arteaga, Carlos L., primary, de la Fuente, Macarena I., primary, Brufksy, Adam M., primary, Spanggaard, Iben, primary, Mau-Sørensen, Morten, primary, Arnedos, Monica, primary, Moreno, Victor, primary, Boni, Valentina, primary, Sohn, Joohyuk, primary, Schwartzberg, Lee S., primary, Gonzàlez-Farré, Xavier, primary, Cervantes, Andrés, primary, Bidard, François-Clement, primary, Gorelick, Alexander N., primary, Lanman, Richard B., primary, Nagy, Rebecca J., primary, Ulaner, Gary A., primary, Chandarlapaty, Sarat, primary, Jhaveri, Komal, primary, Gavrila, Elena I., primary, Zimel, Catherine, primary, Selcuklu, S. Duygu, primary, Melcer, Myra, primary, Samoila, Aliaksandra, primary, Cai, Yanyan, primary, Scaltriti, Maurizio, primary, Mann, Grace, primary, Xu, Feng, primary, Eli, Lisa D., primary, Dujka, Melanie, primary, Lalani, Alshad S., primary, Bryce, Richard, primary, Baselga, José, primary, Taylor, Barry S., primary, Solit, David B., primary, Meric-Bernstam, Funda, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Methods, Figure Legends, Tables S1 - S4 from An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

Author

Hanker, Ariella B., primary, Brewer, Monica Red, primary, Sheehan, Jonathan H., primary, Koch, James P., primary, Sliwoski, Gregory R., primary, Nagy, Rebecca, primary, Lanman, Richard, primary, Berger, Michael F., primary, Hyman, David M., primary, Solit, David B., primary, He, Jie, primary, Miller, Vincent, primary, Cutler, Richard E., primary, Lalani, Alshad S., primary, Cross, Darren, primary, Lovly, Christine M., primary, Meiler, Jens, primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

22. Data from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

23. Data from An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

Author

Hanker, Ariella B., primary, Brewer, Monica Red, primary, Sheehan, Jonathan H., primary, Koch, James P., primary, Sliwoski, Gregory R., primary, Nagy, Rebecca, primary, Lanman, Richard, primary, Berger, Michael F., primary, Hyman, David M., primary, Solit, David B., primary, He, Jie, primary, Miller, Vincent, primary, Cutler, Richard E., primary, Lalani, Alshad S., primary, Cross, Darren, primary, Lovly, Christine M., primary, Meiler, Jens, primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 1 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Fig 3 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Fig 1 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Fig 4 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data from Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Piha-Paul, Sarina A., primary, Won, Helen H., primary, Schram, Alison M., primary, Saura, Cristina, primary, Loi, Sherene, primary, Lu, Janice, primary, Shapiro, Geoffrey I., primary, Juric, Dejan, primary, Mayer, Ingrid A., primary, Arteaga, Carlos L., primary, de la Fuente, Macarena I., primary, Brufksy, Adam M., primary, Spanggaard, Iben, primary, Mau-Sørensen, Morten, primary, Arnedos, Monica, primary, Moreno, Victor, primary, Boni, Valentina, primary, Sohn, Joohyuk, primary, Schwartzberg, Lee S., primary, Gonzàlez-Farré, Xavier, primary, Cervantes, Andrés, primary, Bidard, François-Clement, primary, Gorelick, Alexander N., primary, Lanman, Richard B., primary, Nagy, Rebecca J., primary, Ulaner, Gary A., primary, Chandarlapaty, Sarat, primary, Jhaveri, Komal, primary, Gavrila, Elena I., primary, Zimel, Catherine, primary, Selcuklu, S. Duygu, primary, Melcer, Myra, primary, Samoila, Aliaksandra, primary, Cai, Yanyan, primary, Scaltriti, Maurizio, primary, Mann, Grace, primary, Xu, Feng, primary, Eli, Lisa D., primary, Dujka, Melanie, primary, Lalani, Alshad S., primary, Bryce, Richard, primary, Baselga, José, primary, Taylor, Barry S., primary, Solit, David B., primary, Meric-Bernstam, Funda, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Fig 6 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figures S1 - S2 from An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

Author

Hanker, Ariella B., primary, Brewer, Monica Red, primary, Sheehan, Jonathan H., primary, Koch, James P., primary, Sliwoski, Gregory R., primary, Nagy, Rebecca, primary, Lanman, Richard, primary, Berger, Michael F., primary, Hyman, David M., primary, Solit, David B., primary, He, Jie, primary, Miller, Vincent, primary, Cutler, Richard E., primary, Lalani, Alshad S., primary, Cross, Darren, primary, Lovly, Christine M., primary, Meiler, Jens, primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Fig 5 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Fig 2 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Author

Li, Bob T., primary, Michelini, Flavia, primary, Misale, Sandra, primary, Cocco, Emiliano, primary, Baldino, Laura, primary, Cai, Yanyan, primary, Shifman, Sophie, primary, Tu, Hai-Yan, primary, Myers, Mackenzie L., primary, Xu, Chongrui, primary, Mattar, Marissa, primary, Khodos, Inna, primary, Little, Megan, primary, Qeriqi, Besnik, primary, Weitsman, Gregory, primary, Wilhem, Clare J., primary, Lalani, Alshad S., primary, Diala, Irmina, primary, Freedman, Rachel A., primary, Lin, Nancy U., primary, Solit, David B., primary, Berger, Michael F., primary, Barber, Paul R., primary, Ng, Tony, primary, Offin, Michael, primary, Isbell, James M., primary, Jones, David R., primary, Yu, Helena A., primary, Thyparambil, Sheeno, primary, Liao, Wei-Li, primary, Bhalkikar, Anuja, primary, Cecchi, Fabiola, primary, Hyman, David M., primary, Lewis, Jason S., primary, Buonocore, Darren J., primary, Ho, Alan L., primary, Makker, Vicky, primary, Reis-Filho, Jorge S., primary, Razavi, Pedram, primary, Arcila, Maria E., primary, Kris, Mark G., primary, Poirier, John T., primary, Shen, Ronglai, primary, Tsurutani, Junji, primary, Ulaner, Gary A., primary, de Stanchina, Elisa, primary, Rosen, Neal, primary, Rudin, Charles M., primary, and Scaltriti, Maurizio, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

Author

LeNoue-Newton, Michele L., primary, Chen, Sheau-Chiann, primary, Stricker, Thomas, primary, Hyman, David M., primary, Blauvelt, Natalie, primary, Bedard, Philippe L., primary, Meric-Bernstam, Funda, primary, Punglia, Rinaa S., primary, Schrag, Deborah, primary, Lepisto, Eva M., primary, Andre, Fabrice, primary, Smyth, Lillian, primary, Dogan, Semih, primary, Yu, Celeste, primary, Wathoo, Chetna, primary, Levy, Mia, primary, Eli, Lisa D., primary, Xu, Feng, primary, Mann, Grace, primary, Lalani, Alshad S., primary, Ye, Fei, primary, Micheel, Christine M., primary, and Arnedos, Monica, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure from The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

Author

Ma, Cynthia X., primary, Luo, Jingqin, primary, Freedman, Rachel A., primary, Pluard, Timothy J., primary, Nangia, Julie R., primary, Lu, Janice, primary, Valdez-Albini, Frances, primary, Cobleigh, Melody, primary, Jones, Jason M., primary, Lin, Nancy U., primary, Winer, Eric P., primary, Marcom, P. Kelly, primary, Thomas, Shana, primary, Anderson, Jill, primary, Haas, Brittney, primary, Bucheit, Leslie, primary, Bryce, Richard, primary, Lalani, Alshad S., primary, Carey, Lisa A., primary, Goetz, Matthew P., primary, Gao, Feng, primary, Kimmick, Gretchen, primary, Pegram, Mark D., primary, Ellis, Matthew J., primary, and Bose, Ron, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Table from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

Author

LeNoue-Newton, Michele L., primary, Chen, Sheau-Chiann, primary, Stricker, Thomas, primary, Hyman, David M., primary, Blauvelt, Natalie, primary, Bedard, Philippe L., primary, Meric-Bernstam, Funda, primary, Punglia, Rinaa S., primary, Schrag, Deborah, primary, Lepisto, Eva M., primary, Andre, Fabrice, primary, Smyth, Lillian, primary, Dogan, Semih, primary, Yu, Celeste, primary, Wathoo, Chetna, primary, Levy, Mia, primary, Eli, Lisa D., primary, Xu, Feng, primary, Mann, Grace, primary, Lalani, Alshad S., primary, Ye, Fei, primary, Micheel, Christine M., primary, and Arnedos, Monica, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table from The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

Author

Ma, Cynthia X., primary, Luo, Jingqin, primary, Freedman, Rachel A., primary, Pluard, Timothy J., primary, Nangia, Julie R., primary, Lu, Janice, primary, Valdez-Albini, Frances, primary, Cobleigh, Melody, primary, Jones, Jason M., primary, Lin, Nancy U., primary, Winer, Eric P., primary, Marcom, P. Kelly, primary, Thomas, Shana, primary, Anderson, Jill, primary, Haas, Brittney, primary, Bucheit, Leslie, primary, Bryce, Richard, primary, Lalani, Alshad S., primary, Carey, Lisa A., primary, Goetz, Matthew P., primary, Gao, Feng, primary, Kimmick, Gretchen, primary, Pegram, Mark D., primary, Ellis, Matthew J., primary, and Bose, Ron, primary

Published
2023
Full Text
View/download PDF

37. Supplemental Legend from Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

Author

Ivanova, Elena, primary, Kuraguchi, Mari, primary, Xu, Man, primary, Portell, Andrew J., primary, Taus, Luke, primary, Diala, Irmina, primary, Lalani, Alshad S., primary, Choi, Jihyun, primary, Chambers, Emily S., primary, Li, Shuai, primary, Liu, Shengwu, primary, Chen, Ting, primary, Barbie, Thanh U., primary, Oxnard, Geoffrey R., primary, Haworth, Jacob J., primary, Wong, Kwok-Kin, primary, Dahlberg, Suzanne E., primary, Aref, Amir A., primary, Barbie, David A., primary, Bahcall, Magda, primary, Paweletz, Cloud P., primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

38. Table S3 from Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Author

Ma, Cynthia X., primary, Bose, Ron, primary, Gao, Feng, primary, Freedman, Rachel A., primary, Telli, Melinda L., primary, Kimmick, Gretchen, primary, Winer, Eric, primary, Naughton, Michael, primary, Goetz, Matthew P., primary, Russell, Christy, primary, Tripathy, Debu, primary, Cobleigh, Melody, primary, Forero, Andres, primary, Pluard, Timothy J., primary, Anders, Carey, primary, Niravath, Polly Ann, primary, Thomas, Shana, primary, Anderson, Jill, primary, Bumb, Caroline, primary, Banks, Kimberly C., primary, Lanman, Richard B., primary, Bryce, Richard, primary, Lalani, Alshad S., primary, Pfeifer, John, primary, Hayes, Daniel F., primary, Pegram, Mark, primary, Blackwell, Kimberly, primary, Bedard, Philippe L., primary, Al-Kateb, Hussam, primary, and Ellis, Matthew J.C., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Tables S1-S5 from Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

Author

Albertella, Mark R., primary, Loadman, Paul M., primary, Jones, Philip H., primary, Phillips, Roger M., primary, Rampling, Roy, primary, Burnet, Neil, primary, Alcock, Chris, primary, Anthoney, Alan, primary, Vjaters, Egils, primary, Dunk, Chris R., primary, Harris, Peter A., primary, Wong, Alvin, primary, Lalani, Alshad S., primary, and Twelves, Chris J., primary

Published
2023
Full Text
View/download PDF

40. Figure S3 from Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

Author

Ivanova, Elena, primary, Kuraguchi, Mari, primary, Xu, Man, primary, Portell, Andrew J., primary, Taus, Luke, primary, Diala, Irmina, primary, Lalani, Alshad S., primary, Choi, Jihyun, primary, Chambers, Emily S., primary, Li, Shuai, primary, Liu, Shengwu, primary, Chen, Ting, primary, Barbie, Thanh U., primary, Oxnard, Geoffrey R., primary, Haworth, Jacob J., primary, Wong, Kwok-Kin, primary, Dahlberg, Suzanne E., primary, Aref, Amir A., primary, Barbie, David A., primary, Bahcall, Magda, primary, Paweletz, Cloud P., primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table S1 from Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

Author

Ivanova, Elena, primary, Kuraguchi, Mari, primary, Xu, Man, primary, Portell, Andrew J., primary, Taus, Luke, primary, Diala, Irmina, primary, Lalani, Alshad S., primary, Choi, Jihyun, primary, Chambers, Emily S., primary, Li, Shuai, primary, Liu, Shengwu, primary, Chen, Ting, primary, Barbie, Thanh U., primary, Oxnard, Geoffrey R., primary, Haworth, Jacob J., primary, Wong, Kwok-Kin, primary, Dahlberg, Suzanne E., primary, Aref, Amir A., primary, Barbie, David A., primary, Bahcall, Magda, primary, Paweletz, Cloud P., primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figures S1, S2, S3 and Tables S1, S2 from Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Author

Ma, Cynthia X., primary, Bose, Ron, primary, Gao, Feng, primary, Freedman, Rachel A., primary, Telli, Melinda L., primary, Kimmick, Gretchen, primary, Winer, Eric, primary, Naughton, Michael, primary, Goetz, Matthew P., primary, Russell, Christy, primary, Tripathy, Debu, primary, Cobleigh, Melody, primary, Forero, Andres, primary, Pluard, Timothy J., primary, Anders, Carey, primary, Niravath, Polly Ann, primary, Thomas, Shana, primary, Anderson, Jill, primary, Bumb, Caroline, primary, Banks, Kimberly C., primary, Lanman, Richard B., primary, Bryce, Richard, primary, Lalani, Alshad S., primary, Pfeifer, John, primary, Hayes, Daniel F., primary, Pegram, Mark, primary, Blackwell, Kimberly, primary, Bedard, Philippe L., primary, Al-Kateb, Hussam, primary, and Ellis, Matthew J.C., primary

Published
2023
Full Text
View/download PDF

43. Figures S1 and S2 from Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial

Author

Sudhan, Dhivya R., primary, Schwarz, Luis J., primary, Guerrero-Zotano, Angel, primary, Formisano, Luigi, primary, Nixon, Mellissa J., primary, Croessmann, Sarah, primary, González Ericsson, Paula I., primary, Sanders, Melinda, primary, Balko, Justin M., primary, Avogadri-Connors, Francesca, primary, Cutler, Richard E., primary, Lalani, Alshad S., primary, Bryce, Richard, primary, Auerbach, Alan, primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

44. Supplemental Data from Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

Author

Croessmann, Sarah, primary, Formisano, Luigi, primary, Kinch, Lisa N., primary, Gonzalez-Ericsson, Paula I., primary, Sudhan, Dhivya R., primary, Nagy, Rebecca J., primary, Mathew, Aju, primary, Bernicker, Eric H., primary, Cristofanilli, Massimo, primary, He, Jie, primary, Cutler, Richard E., primary, Lalani, Alshad S., primary, Miller, Vincent A., primary, Lanman, Richard B., primary, Grishin, Nick V., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

45. Data from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

Author

LeNoue-Newton, Michele L., primary, Chen, Sheau-Chiann, primary, Stricker, Thomas, primary, Hyman, David M., primary, Blauvelt, Natalie, primary, Bedard, Philippe L., primary, Meric-Bernstam, Funda, primary, Punglia, Rinaa S., primary, Schrag, Deborah, primary, Lepisto, Eva M., primary, Andre, Fabrice, primary, Smyth, Lillian, primary, Dogan, Semih, primary, Yu, Celeste, primary, Wathoo, Chetna, primary, Levy, Mia, primary, Eli, Lisa D., primary, Xu, Feng, primary, Mann, Grace, primary, Lalani, Alshad S., primary, Ye, Fei, primary, Micheel, Christine M., primary, and Arnedos, Monica, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 3 from Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition

Author

Daly, Christopher, primary, Eichten, Alexandra, primary, Castanaro, Carla, primary, Pasnikowski, Elizabeth, primary, Adler, Alexander, primary, Lalani, Alshad S., primary, Papadopoulos, Nicholas, primary, Kyle, Alastair H., primary, Minchinton, Andrew I., primary, Yancopoulos, George D., primary, and Thurston, Gavin, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure Legends 1-4 from Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition

Author

Daly, Christopher, primary, Eichten, Alexandra, primary, Castanaro, Carla, primary, Pasnikowski, Elizabeth, primary, Adler, Alexander, primary, Lalani, Alshad S., primary, Papadopoulos, Nicholas, primary, Kyle, Alastair H., primary, Minchinton, Andrew I., primary, Yancopoulos, George D., primary, and Thurston, Gavin, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 4 from Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition

Author

Daly, Christopher, primary, Eichten, Alexandra, primary, Castanaro, Carla, primary, Pasnikowski, Elizabeth, primary, Adler, Alexander, primary, Lalani, Alshad S., primary, Papadopoulos, Nicholas, primary, Kyle, Alastair H., primary, Minchinton, Andrew I., primary, Yancopoulos, George D., primary, and Thurston, Gavin, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Table 1 from Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition

Author

Daly, Christopher, primary, Eichten, Alexandra, primary, Castanaro, Carla, primary, Pasnikowski, Elizabeth, primary, Adler, Alexander, primary, Lalani, Alshad S., primary, Papadopoulos, Nicholas, primary, Kyle, Alastair H., primary, Minchinton, Andrew I., primary, Yancopoulos, George D., primary, and Thurston, Gavin, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results